Biologics Contract Development Market Size, Share Analysis and Growth Forecast 2032

The Biologics Contract Development Market is being driven by the increasing demand for biologics and the outsourcing of contract development services. In 2022, the market size was USD 10.19 Billion, and it is expected to grow at a CAGR of 7.3%, reaching USD 19.21 Billion by 2032. One of the key trends in the market is the growing demand for personalized medicine and the emergence of new markets for biologics.

According to a recent report by Reports and Data, the global biologics contract development market size was USD 10.19 Billion in 2022, and it is projected to experience a revenue CAGR of 7.3% during the forecast period.

Biologics are complex compounds derived from living cells and are utilized for the treatment of various diseases such as cancer, autoimmune disorders, and viral infections. The market revenue growth is primarily fueled by the increasing incidence of chronic illnesses, an aging population, and advancements in biologics manufacturing technology.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/6096

Some of the major companies included in the biologics contract development market report are:

Lonza Group AG
Catalent, Inc.
Thermo Fisher Scientific Inc.
Boehringer Ingelheim International GmbH
Samsung Biologics
WuXi Biologics
AbbVie Inc.
Pfizer Inc.
Merck Co., Inc.
Charles River Laboratories International, Inc.

The demand for personalized medicine is driving the growth of the biologics market. Personalized medicine involves tailoring treatment plans based on an individual's DNA profile and other relevant factors. Biologics, with their ability to target specific cells and molecules in the body, are gaining popularity in customized therapy. As a result, companies are outsourcing the development of these specialized drugs to meet the demand for personalized medicine, leading to revenue growth in the market.

The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular disease, is also contributing to the demand for biologics. Despite their ability to target specific cells and molecules, biologics are increasingly being used to treat a wide range of conditions due to their effectiveness and reduced side effects. As a result, companies are outsourcing the development of these medications to specialized contract development organizations, driving revenue growth in the biologics contract development market.

The growing utilization of biologics in emerging economies is another factor driving market revenue growth. Countries like China, India, and Brazil, with their increasing demand for innovative medical treatments and expanding healthcare infrastructure, are expected to play a significant role in the revenue growth of the global biologics market. The adoption of biologics in these markets is likely to fuel revenue growth in the biologics contract development market as companies opt to outsource the development of these treatments to specialized organizations.

Furthermore, the complexity of biologics development and the need for specialized expertise are contributing to revenue growth in the biologics contract development market. Given the intricate nature of biologics, their study, manufacturing, and testing require specialized knowledge. Many companies are choosing to outsource the development of these therapies to contract development organizations that possess the necessary skills and experience, thus driving revenue growth in the market.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.reportsanddata.com/report-detail/biologics-contract-development-market

Key highlights from the report include:

The discovery segment is projected to hold the largest share of revenue during the forecast period. This segment involves identifying new therapeutic targets and developing potent drug candidates, which are crucial stages in biologics development. The increasing demand for biologics, especially in emerging markets, is expected to drive revenue growth in the discovery segment.
The monoclonal antibodies segment generated the highest revenue in 2022. The demand for monoclonal antibodies has risen for the treatment of various conditions such as cancer, autoimmune disorders, and infectious diseases. Revenue growth in this segment is also driven by an aging population and the prevalence of chronic diseases. The use of monoclonal antibodies in precision medicine has further contributed to the high demand for these products.
North America dominated the market in 2022, with the largest revenue share. This can be attributed to the region's high demand for biologics development services and significant investments in biologics research and development. The presence of major pharmaceutical and biotechnology companies like Amgen, Biogen, and Pfizer contributes to the growth of the biologics contract development market in North America. Additionally, the increasing prevalence of chronic diseases, including cancer and autoimmune disorders, is fueling the demand for biologic medicines, thereby boosting revenue growth in the North American market.
Catalent, Inc. acquired MaSTherCell Global, a cell and gene therapy contract development and manufacturing company based in Belgium, on February 10, 2020. This acquisition aimed to strengthen Catalent's capabilities in cell and gene therapy and expand its presence in Europe.
Boehringer Ingelheim International GmbH announced the expansion of its biologics development and production facilities in China on December 30, 2019. The expansion aims to meet the growing demand for biologics pharmaceuticals in China and the Asia Pacific region.
Catalent Pharma Solutions introduced GPEx Boost, a novel cell line development technique, on November 4, 2019. This technique enables higher expression levels and shorter cell line development timelines, facilitating the rapid development of high-producing stable cell lines and enhancing quality control in the biomanufacturing process.
Lonza Group Ltd. launched the MODA ES Software Platform in 2019, an electronic batch record (EBR) software designed for the biopharmaceutical production process. This platform provides real-time insight and control over critical manufacturing processes, reducing the risk of errors and accelerating biologics production.

Custom Requirements can be requested for this Report [Customization Available] @ https://www.reportsanddata.com/request-customization-form/6096

For the purpose of this report, Reports and Data has segmented the global biologics contract development market on the basis of Service Type Outlook, Product Type Outlook, End-use Outlook, and Regional Outlook:

Service Type Outlook (Revenue, USD Billion; 2022 - 2032)

Discovery
Preclinical
Clinical
Manufacturing

Product Type Outlook (Revenue, USD Billion; 2022 - 2032)

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Others

End-use Outlook (Revenue, USD Billion; 2022 - 2032)

Pharmaceutical Biopharmaceutical Companies
Academic Research Institutes
Contract Research Organizations

Regional Outlook (Revenue, USD Billion; 2022-2032)

North America

U.S.
Canada
Mexico

Europe

Germany
U.K.
France
Italy
Spain
Sweden
BENELUX
Rest of Europe

Asia-Pacific

China
India
Japan
South Korea
Rest of APAC

Latin America

Brazil
Rest of LATAM

Middle East Africa

Saudi Arabia
UAE
South Africa
Israel
Rest of MEA

Latest Research Reports Published by Reports and Data:

Cancer Biomarkers Market by Type (Protein Biomarkers, Genetic Biomarkers, Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Others), By Application (Diagnosis, Prognosis, Treatment), By Region Forecast to 2032

Cardiac Biomarkers Market Analysis, By Product Type (Troponin, Myocardial muscle Creatine Kinase, Ischemia Modified Albumin, Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome), by Location of Testing, by End user, Forecasts to 2028

Cardiac Arrhythmias Monitoring Devices Market By Type (Implantable, Wearable, External), By Application (Hospitals, Clinics, Home Care Settings, Others), By Region Forecast to 2032

Obesity Treatment Market, By Treatment Type (Dietary Changes, Exercise and Physical Activity, Behavioral Therapy, and Others), By Prescription Medication (Orlistat, Lorcaserin, Phentermine and Topiramate, and Others), By End-Use, and By Region Forecast to 2032

Sacral Neuromodulation Market, By Product Type (Rechargeable and Non-rechargeable), By Application (Urinary Incontinence, Fecal Incontinence, and Chronic Pain), By End-Use (Hospitals, Ambulatory Surgery Centers, Clinics, and Others), and By Region Forecast to 2032

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Read our Press Release @ https://www.reportsanddata.com/press-release/global-biologics-contract-development-market